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Jin Shao1†, Weiwei Zhang2*† and Tieyi Yang1*
Abstract 
Bone is a unique tissue which could regenerate completely after injury rather than heal itself with a scar. Compared 
with other tissues the difference is that, during bone repairing and regeneration, after the inflammatory phase the 
mesenchymal stem cells (MSCs) are recruited to the injury site and differentiate into either chondroblasts or osteo‑
blasts precursors, leading to bone repairing and regeneration. Besides these two precursors, the MSCs can also dif‑
ferentiate into adipocyte precursors, skeletal muscle precursors and some other mesodermal cells. With this multiline‑
age potentiality, the MSCs are probably used to cure bone injury and other woundings in the near future. Here we 
will introduce the recent developments in understanding the mechanism of MSCs action in bone regeneration and 
repairing.
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Introduction
In 1964 Till et al. gave us the idea and definition of stem 
cell-self-renewal and differentiation [1]. Nowadays clini-
cally it is a common understanding that the regenerative 
medicine is dependent on the properties of stem cells [2]. 
Mesenchymal stem cells (MSCs) are thought to be essen-
tial for bone-healing because of its ability to differentiate 
in vitro into both chondrocytes and osteocytes, and pro-
vide great potential for tissue engineering.
Tissue engineering is to replace tissues through the 
usage of specific cell types when the tissue function or 
structure is lost because of trauma or disease. Usually a 
3D scaffold with various growth factors, cytokines, hor-
mones and other biological molecules will be utilized 
during the engineering, in order to facilitate the genera-
tion of a critical mass of specific precursor cells and their 
differentiation into the required cell type.
As the key process in tissue engineering is to gener-
ate enough amount of a certain cell type, stem cells are 
thought to be the proper starting cells in clinical practice. 
They could be collected from various tissues, for exam-
ple bone marrow, adipose, amniotic fluid, umbilical cord 
blood and even breast milk [3–6]. Among these origins, 
bone marrow-derived MSCs are the most commonly uti-
lized stem cells for bone repairing, both in research and 
clinical practice [7]. There are several reports indicating 
that the transplantation of bone marrow-derived MSCs 
promotes bone formation at sites of bone defects [8–10]. 
In this review we will give a brief introduction of MSCs 
and importance of its usage in tissue repairing.
Characteristics of MSCs
Self-renewal is a hallmark of all stem cells [1]. The main-
tenance of self-renewal and pluripotency of stem cells 
occurs in the stem cell niche, where stem cells are able to 
receive signals from the stroma or other cells via contact 
or secreted molecules within this niche [11, 12]. Adult 
MSCs also share this kind of ability and could differen-
tiate not only into osteoblasts, adipocytes, and chon-
drocytes, but also into cells of non-mesodermal lineages 
including hepatocytes, neuron-like cells, and pancreatic 
cells [13–17].
MSCs could be easily distinguished from other bone 
marrow cells by their rapid adherence to plastic and their 
fibroblast-like morphology [18]. For decades cultured 
Open Access
*Correspondence:  zhangweiw1980@126.com; yangtieyiyi@126.com 
†Jin Shao and Weiwei Zhang contributed equally to this work
1 Department of Orthopaedics, Shanghai Pudong New Area Gongli 
Hospital, Second Military Medical University, Shanghai 200135, China
2 State Key Laboratory of Oncogenes and Related Genes, Renji‑Med X 
Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, 
Shanghai Jiao Tong University, Shanghai 200127, China
Full list of author information is available at the end of the article
Page 2 of 7Shao et al. Biol Res  (2015) 48:62 
plastic-adherent bone marrow cells are the main source 
of MSCs, but now MSCs could also be derived from 
other tissues, such as placenta, adipose tissue, periph-
eral blood, umbilical blood and so on [19–22]. In vitro 
bone marrow-derived MSCs express the surface markers 
CD105, CD90 and CD73, but lack CD45, CD34, CD14, 
CD11b, CD7a and CD19 [23–26]. There are also some 
MSCs expressing markers, such as CD271 [23]. However, 
it is lack of evidences showing all the human MSCs have 
those markers. MSCs derived from different sources also 
vary in their differentiation capacity. As bone marrow-
derived MSCs have better chondrogenic differentiation 
potential, they are considered to be a proper source for 
the therapy which facilitates bone repairing and regen-
eration [27, 28].
Besides the differentiation potential, MSCs also have 
immune-suppressive activity, which together with their 
paracrine function plays an essential role in bone regen-
eration and repairing [28]. This issue will be discussed in 
the section “Mechanism of MSCs action”.
Differentiation capacity of MSCs
Bone marrow‑derived MSCs for Bone Engineering
MSCs exist in most of the postnatal tissues, and they all 
have differentiation capacity and the potential to be uti-
lized in tissue engineering. Theoretically all the MSCs 
have the ability to differentiate towards osteogenic, chon-
drogenic and adipogenic lineages. They could be success-
fully expanded in  vitro and induced to different types 
of subsets when the optimal cultivation protocols were 
used [29, 30]. As bone marrow-derived MSCs have the 
strongest chondrogenic differentiation potential, they are 
thought to be a better choice for bone engineering than 
the other MSCs sources [27].
Chondrogenic and osteogenic potential of MSCs in vitro
Even though MSCs with different origins have differ-
ences in differentiation capacity, all of them could be 
derived into osteoblasts and chondrocytes, which are 
essential in bone repairing. The tendency to differenti-
ate into a certain cell lineage is usually dependent on 
the culture conditions. Bone marrow-derived MSCs 
have the highest potential to generate chondrocytes and 
osteoblasts. And the standard protocol for chondro-
genesis was first established for bone marrow-derived 
MSCs. In this standard protocol growth factors from 
transforming growth factor β (TGF-β) superfamily are 
the key factors which facilitate chondrogenic differen-
tiation of MSCs [31, 32]. Previous studies showed that 
these factors regulate MSCs differentiation via several 
signaling pathways, such as Smad, extracellular signal-
regulated kinase 1/2 and c-Jun N-terminal kinase path-
ways [33–36].
MSCs derived from other tissues may also be used in 
clinic because of their advantages. For example, adipose-
derived MSCs are easy to obtain, and umbilical cord-
derived MSCs have high differentiation capacity and can 
be stored after birth and used as autologous implantation 
or tissue engineering. In cultivation with some certain 
growth factors such as TGF-β and bone morphogenetic 
protein-6 (BMP-6), adipose-derived MSCs can express 
cartilage-specific proteins such as type II collagen, but 
they do not express hypertrophic chondrocyte markers 
such as type X collagen [37–39]. In 2010 a standard pro-
tocol for isolation of adipose-derived MSCs and induc-
tion to chondrogenesis was published in Nature, which is 
very useful in practice [38]. However, in comparison with 
bone marrow-derived MSCs, the chondrogenic potential 
of adipose-derived MSCs is quite limited.
Apart from the prominent advantages of umbilical 
cord-derived MSCs, such as a painless collection pro-
cedure and fast self-renewal, they also have a very high 
differentiation capacity including chondrogenic poten-
tial. Not like bone marrow-derived MSCs, umbilical 
cord-derived MSCs show a gene expression pattern more 
similar to embryonic stem cells (ESCs), and with proper 
expansion they could be used as a therapy not only for 
bone injury but also for other tissues repairing, even for 
neural injury. The most appreciable advantage of umbili-
cal cord-derived MSCs is that the collection procedure 
is noninvasive and ethically acceptable [40–42]. Maybe 
in the future with a proper inducing method, umbilical 
cord-derived MSCs could be a better choice for bone 
engineering.
Influence of oxygen and mechanical stimulation on MSCs 
differentiation
Besides the culture and growth factors, O2 partial pres-
sure and mechanical stimulation are also important fac-
tors influencing MSCs differentiation. Usually cells are 
cultured under normoxic (21  % O2) conditions. How-
ever, most of the cells in vivo are not under such a high 
O2 concentration. For example, there is no vascular tis-
sue in cartilage, thus the microenvironment in cartilage is 
hypoxic, where the O2 concentration is about 1–5 % [43]. 
Bone marrow is also under hypoxic condition in vivo and 
the O2 concentration there is about 1–7 % [44]. Though 
adipose tissue is a vascularized tissue, the O2 concentra-
tion there is only about 10–15 % [45]. It has been showed 
that hypoxia promotes chondrogenesis rather than osteo-
genesis [46–49]. When bone marrow-derived MSCs are 
expanded under low O2 concentration (5 %), the subse-
quent osteogenesis would be enhanced [50]. In practice, 
it is a simple way to control the differentiation of MSCs 
using O2. Furthermore, the cell fate can be changed with-
out adding some expensive biological factors.
Page 3 of 7Shao et al. Biol Res  (2015) 48:62 
Mechanical forces, which are generated within the 
cell in response to its extracellular environment and 
extrinsic mechanical signals, play a central role in 
determining MSC fate. Though the exact mechanism 
of mechanical sensitivity and respond is still not clear, 
it is believed that integrins and ion channels partici-
pate in this mechanotransduction progress [51]. It has 
been demonstrated that MSCs respond to oscillatory 
fluid flow with intracellular Ca2+ transient increasing, 
and then increase the proliferation rate, up-regulate 
osteoblastic gene expression and down-regulate alka-
line phosphatase activity [52]. The fact that oscillatory 
fluid flow could up-regulate the expression of Runx2, 
Sox9 and PPARγ in MSCs, suggested that this kind of 
mechanical stimuli could regulate gene expression of 
some transcription factors which participate in MSCs 
differentiation [53, 54].
Mechanisms of MSCs action in bone regeneration 
and repairing
MSCs contribute to bone regeneration and repairing
With the achievements in the identification, isolation, 
and cultivation of MSCs, it is not difficult to develop 
improved technologies for defining therapeutic MSCs 
and MSC-based bone repairing. In 1998 a study dem-
onstrated that implantation of a bone marrow-derived 
MSCs supplemented scaffold leaded to bone regenera-
tion in bone fracture. On the other hand, implanted scaf-
fold without MSCs had no such function [55]. Further 
studies indicated that pre-differentiated osteogenetic 
MSCs supplemented scaffold had superior healing effects 
[56, 57]. More interestingly, delivery of MSCs into clini-
cal models of diabetes resulted in higher fracture healing 
activity than those did not received MSCs [58].
It is believed that MSCs can differentiate into skeletal 
progenitor cells which generate skeletal tissues in  vivo. 
Transplanted CD45−CD146+ human bone marrow-
derived MSCs have the capacity to generate ectopic 
bones and hematopoietic microenvironment in  vivo 
[59]. Further studies by Omatsu et al. demonstrated that 
perivascular MSCs which express CXCL12 were essential 
for hematopoietic stem cells (HSCs) proliferation [60], 
and in this way play a role in angiogenesis. As we know, 
osteogenesis is strongly associated with angiogenesis, it is 
not difficult to speculate that angiogenesis also contrib-
utes to bone regeneration and repairing.
In the early days bone marrow-derived MSCs were 
thought to achieve their functions via replacing the cells 
in damaged tissues, but recently it was found that MSCs 
could also provide paracrine signals to repair vascular 
injury or modulate pathological immune responses [61]. 
This issue will be discussed later.
MSCs homing to the injury site
The way MSCs home to the injury site is still not clear, 
anyway chemoattractant molecules released at the bone 
injury site must play an essential role in MSCs attract-
ing. It has been known that MSCs express at least 19 
chemokine receptors [62]. Stromal cell-derived fac-
tor 1 (SDF-1) expressed by stromal niche is the primary 
attractant for CXCR4-expressing MSCs and during 
trauma CXCR4 is up-regulated by MSCs [63, 64]. Many 
other chemotactic factors such as RANTES, macrophage 
inflammatory protein-1α (MIP-1α), monocyte chemotac-
tic protein 1 (MCP-1) and so on, also work on MSCs. All 
these indicate that MSCs homing is attractant/receptor 
dependent [65]. However, the negative side of the homing 
property of MSCs is that they may home to other tissues 
even developing tumors [66, 67] or undergo necrosis/
apoptosis, which is very harmful.
Direct and indirect contributions of MSCs
MSCs display a broad differentiation capacity in vitro, it 
was originally hypothesized MSCs transplantation would 
induce tissue repairing by replacing cells in the damaged 
host tissue. During bone repairing, the progenitor cells 
will migrate to the injury site and differentiate into osteo-
blasts and chondrocytes, and then lead to bone remod-
eling [68, 69].
Despite the long-lasting therapeutic efficacy of MSCs 
in many in  vivo models (such as bone and cartilage 
repairing, cardiovascular and neurological diseases), the 
incidence of MSCs engraftment remained surprisingly 
low [70, 71]. This unexpected low engraftment efficacy 
implied a major challenge to explain the beneficial effects 
of the MSCs. Accumulating evidences indicated that the 
general therapeutic effects of MSCs are due to their abil-
ity to modify the host micro-environment rather than 
their capacity to differentiate and incorporate into the 
host tissue.
In mice it has been observed that transplanted MSCs 
migrate to the site of fractures, integrate into the cal-
lus and secrete BMP-2 which acts as a disulfide-linked 
homodimer and induces bone and cartilage formation. It 
is a candidate as a retinoid mediator, playing a key role in 
osteoblast differentiation [72]. Adding vascular endothe-
lial growth factor (VEGF) together with BMPs could 
facilitate both osteogenesis and angiogenesis, leading to 
higher bone formation activity and mechanical strength 
[73]. Transplanted osteoblastic progenitors repair the 
fracture via intramembranous ossification, while less dif-
ferentiated MSCs lead to endochondral ossification, a 
process reminiscent of embryonic skeletal development. 
This indicates that bone repairing function of MSCs is 
based on its maturation state [74].
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It is commonly accepted that osteogenesis is associated 
with angiogenesis. Studies by De Luca et al. demonstrated 
that the secretion of angiogenic factors by MSCs could be 
increased when trauma happened. Under chemokines 
and hypoxic conditions, TGF-α induces the secretion of a 
range of growth factors such as VEGF, hepatocyte growth 
factor (HGF), interleukin 6 (IL-6), IL-8, platelet-derived 
growth factor subunit B (PDGF-BB), angiopoietin-2 
(Ang-2) and so on in bone marrow-derived MSCs via 
MEK/MAPK and PI3 K/AKT pathways [75]. The angio-
genesis process is very complicated involving endothelial 
cell (EC) survival, proliferation, migration, tube forma-
tion and maturation. With the help of MSCs paracrine 
signal, angiogenesis could be enhanced. In turn this angi-
ogenic function changes the micro-environment of the 
damaged tissue and then benefits osteogenesis.
The ability to regulate immune response is another 
important contribution of MSCs during bone repairing. 
It was reported that MSCs transplantation leads to higher 
survival rates in graft-versus-host disease than usual [76]. 
MSCs modulate the inflammatory micro-environment at 
the trauma site and decrease the levels of IL-1β, IL-6 and 
tumor necrosis factor-α (TNF-α) [72]. As TNF-α is up-
regulated in the injury or fracture sites [77], the function 
of MSCs results in a limited inflammation reaction which 
facilitates osteogenesis and angiogenesis and in turn con-
tributes to bone repairing. It is now clear that TNF-α 
recruits osteoclasts and MSCs to the trauma site and 
causes apoptosis of hypertrophic chondrocytes in order 
to facilitate endochondral ossification [78]. Because of 
the osteoclastic activity, high level of TNF-α can inhibit 
bone repairing [79]. Thus transplantation of MSCs could 
Fig. 1 Proposed mechanisms of action of MSCs transplantation. Paracrine effects of MSCs include the stimulation of angiogenesis, protection of 
other cells from apoptosis, recruitment of host MSCs or other progenitor cells and stimulation of their proliferation and differentiation [82, 83]. The 
immunomodulatory effects of MSC consist of inhibiting the proliferation and activity of neutrophils, NK cells, B cells, CD4+ cells and CD8+ T cells, 
preventing the maturation of monocytes into dendritic cells, suppressing plasma cell immunoglobulin production but stimulating proliferation of 
regulatory T cells [84]. In some physiological settings, MSCs are able to differentiate into multiple cell types and transfer vesicles containing mRNA, 
miRNA, proteins and perhaps mitochondria to the host cells [81, 84, 85]
Page 5 of 7Shao et al. Biol Res  (2015) 48:62 
regulate exaggerated immune responses and then facili-
tates fracture repair.
Another study demonstrated that factors released by 
bone marrow derived MSCs could recruit macrophages 
and endothelial lineage cells into the wound thus enhanc-
ing wound healing [80]. Together, the transplanted MSCs 
could modify the local micro-environment such as angi-
ogenesis, and suppress exaggerated immune reaction, 
and therefore lead to bone repairing. Even though the 
detailed mechanism of the exogenously implanted MSCs 
therapy is still not clear, its potential is quite promising.
Now there are also evidences indicating that MSCs 
could possibly transfer mitochondria or vesicular com-
ponents which contain mRNA, miRNA or proteins [81]. 
Generally speaking, the basic mechanisms of MSCs action 
on bone regeneration and repairing are as following 
(Fig. 1): replacing the damaged cells by proliferation and 
differentiation; the modulation of the immune system; the 
secretion of factors that induce tissue repair; recruitment 
of endogenous MSCs or progenitor cells to the injury site; 
possible transfer of mitochondria or vesicular compo-
nents containing mRNA, miRNA and proteins.
Discussion
Although MSCs were studied because of their differenti-
ation capacity, there is now accumulating evidences sug-
gesting that immunomodulatory and paracrine actions 
predominantly contribute to their therapeutic efficacy. 
Some molecules such as VEGF, BMP-2 and MCP-1 play 
essential roles in the mechanism of MSCs induced tissue 
regeneration.
Since 1995 more than 3000 patients have received 
autologous culture-expanded MSCs implantation as a 
therapy, no serious adverse reaction was reported [86, 
87]. However, some unsolved issues still prevent these 
promising cells to become a realistic treatment option for 
the future, for example, the absence of a unique marker 
for MSCs, unstable MSCs isolation and expansion, and 
recent pre-clinical reports raise the concern that MSCs 
may cause harmful ectopic bone formation [88]. In order 
to solve these problems, more preclinical researches 
about their differentiation capacity and potential effect 
on the microenvironment need to be done.
In conclusion, over the last decade, numerous studies 
have been done on MSCs. This is evidenced by the suc-
cessful application in a wide variety of in  vivo wound 
healing, resulting in an increasing optimism of both basic 
scientists and clinicians. Besides bone regeneration and 
repairing, MSCs could be engineered for anti-cancer 
treatments, designed as carriers for certain factors or 
genes [89]. Though it is now still impossible to let MSCs 
become an everyday therapeutic option, routine clinical 
application of MSCs for a wide variety of pathologies 
associated with limited angiogenesis, osteogenesis and 
chondrogenesis is an exciting prospect.
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